This second set of human TMA analyses further confirms that CCL2/STAT3/Snail could be important markers with prognostic value, and targeting the CCL2/CCR2 axis may represent a potential new therapeutic approach to battle PCa, especially preventing the development of CRPC. This evidence concerns the gene SNAI1 and posterior cortical atrophy.